Clinical Trial Update: Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Sugemalimab (or placebo) plus the PGemOx regimen in Extranodal NK/T-cell lymphoma; the trial status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma Nasal Type

Drugs mentioned

• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)
• Sugemalimab (sugemalimab)

Snippet

Sponsor: CStone Pharmaceuticals | Conditions: Extranodal NK/T-cell Lymphoma | Phase 3 | Status: NOT_YET_RECRUITING